Sam Brusco, Associate Editor09.21.22
Soft tissue healing company Embody Inc. has closed a $10.4 million Series C funding round.
Embody aims to use the financing to expand its operations and postmarket clinical studies of its recently launched Tapestry RC (rotator cuff) system. The company will also use the funds to prepare for commercial launch of its ActivBraid collagen-based suture tech in 2023.
"This financing represents a notable step in the continued growth of Embody" Jeff Conroy, Embody's founder and CEO told the press. "We are thrilled to have the continued support of our highly seasoned investor base, further illustrating the opportunity and need of our soft tissue healing technology portfolio."
Embody’s novel, collagen-based bio-fabrication techniques and products serve the sports medicine market, including rotator cuff repair, foot/ankle, and knee.
"Embody's collagen technologies have the potential to redefine the standard of care and approaches to the treatment of tendon and ligament injuries," noted Genesis Innovation Group and the cultivate(MD) venture funds Executive Director, R. Sean Churchill, MD, MBA. "We are proud to partner with Embody and believe the technology and team are well positioned to be a leader in the sports medicine market space."
Embody aims to use the financing to expand its operations and postmarket clinical studies of its recently launched Tapestry RC (rotator cuff) system. The company will also use the funds to prepare for commercial launch of its ActivBraid collagen-based suture tech in 2023.
"This financing represents a notable step in the continued growth of Embody" Jeff Conroy, Embody's founder and CEO told the press. "We are thrilled to have the continued support of our highly seasoned investor base, further illustrating the opportunity and need of our soft tissue healing technology portfolio."
Embody’s novel, collagen-based bio-fabrication techniques and products serve the sports medicine market, including rotator cuff repair, foot/ankle, and knee.
"Embody's collagen technologies have the potential to redefine the standard of care and approaches to the treatment of tendon and ligament injuries," noted Genesis Innovation Group and the cultivate(MD) venture funds Executive Director, R. Sean Churchill, MD, MBA. "We are proud to partner with Embody and believe the technology and team are well positioned to be a leader in the sports medicine market space."